Investor Overview

2018 was a strong year for our Tiara and Reducer product platforms. Both have achieved significant therapy development milestones, putting Neovasc on a stronger foundation from which to continue advancing these products commercially. We also have a clear value creation strategy for patients, employees, and investors. All of this is really good news for our outlook.

Read More >

Latest News

Neovasc Reducer™ Therapy for Refractory Angina Exceeds 200th Patient Milestone in Germany

> read full release

Archive >

Programs and Events

Stifel Healthcare Conference

Fred Colen's presentation via webcast
Nov. 20, 2019, 4:10 p.m. ESTregister >

13th Annual Cannacord Genuity Forum

Fred Colen's presentation via webcast
Nov. 21, 2019, 10:00 a.m. EST)register >

Neovasc Presentation - November 2019

.pdf format >

Neovasc @
Stifel Healthcare Conference

Fred Colen’s presentation via webcast
Nov. 20, 2019, 4:10 p.m. EST

register >

Neovasc @
Cannacord Healthcare Conference

Fred Colen’s presentation via webcast
Nov. 21, 2019, 10:00 a.m. EST

register >

Neovasc @
PCR London Valves 2019

Rapid Fire Session – updates from the world of TMVR
Interventions for Valvular Disease, Mitral Valve Replacement and Repair
Nov. 19, 2019, 13:10-14:40
Excel London, Room 3/Level 01

learn more >

Financial Report Archives

2019 Financial Reports

News Release Archives

2019 News Releases

Share Information

Auditor
Grant Thornton LLP, Vancouver, BC

Legal Counsel
Blakes LLP, Vancouver, BC

Transfer Agent
Computershare, Vancouver, BC

Investor Relations
Chris Clark, Chief Financial Officer
investors@neovasc.com

To automatically receive news updates

register now